TheraCryf PLC (TCF)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

0.18p

Buy

0.22p

arrow-up0.008p (+4.00%)

Prices updated at 19 Dec 2025, 12:29 GMT

Prices minimum 15 mins delay

Prices in GBX

Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Its pipeline is based on Sulforadex technology which includes synthetic and stabilized analogues of sulforaphane.

FTSE All-Share

0.17%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Alastair Maclaughlin Smith

CEO

Dr. Huw Jones

Most recent earnings

31 Mar 2025

Fiscal year end

31 Mar 2025

Employees

9

Head office

Congleton Road

Nether Alderley

United Kingdom

SK10 4TG

+44 1625315090

enquiries@evgen.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Alan John Barge Non-Executive Director, Senior Independent Director	-
Dr. Alastair Maclaughlin Smith Non-Executive Director, Chairman	-
Mr. Edward Wardle Non-Executive Director	-
Mr. Toni Markus Antero Haenninen Executive Director, Chief Financial Officer	-
Dr. Huw Jones Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Crux Asset Management Limited	62,150,000
TM Oberon UK Smaller Companies Fund	62,150,000
Chelverton Asset Management Ltd	-
MI Chelverton UK Equity Growth Fund	-

Director dealings

Date chevron-l-regular chevron-r-regular	Action
14 Oct 2025	Purchase
21 May 2025	Purchase
02 May 2025	Purchase
21 Feb 2025	Purchase
21 Feb 2025	Purchase
21 Feb 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.